CEO Ian Akash Morrison Highlighted Translational Oncology Strategy and Clinical Development Roadmap
Los Angeles, CA – 2025 — Avesta Bio, a translational oncology company developing first-in-class therapies targeting cellular stress-response and drug-resistance pathways, has been selected to present at the 27th Annual SoCalBio Investor & Partnering Conference. CEO and Co-Founder Ian Akash Morrison represented the company at the event.
The SoCalBio Investor & Partnering Conference is one of the leading life sciences gatherings in Southern California, bringing together biotechnology executives, venture capital firms, institutional investors, pharmaceutical partners, and strategic advisors. Companies selected to present are recognized for scientific merit, development progress, and potential for clinical and commercial impact.
During the presentation, Mr. Morrison outlined Avesta Bio’s platform strategy focused on correcting maladaptive stress-response programs implicated in tumor progression and therapeutic resistance. The discussion also addressed the company’s regulatory pathway, IND-enabling progress, and advancement toward Phase I clinical evaluation.
“We are honored to be selected to present at SoCalBio,” said Ian Akash Morrison, CEO of Avesta Bio. “This conference brings together some of the most thoughtful investors and strategic partners in the life sciences ecosystem. We look forward to sharing our progress and our disciplined approach to advancing first-in-class oncology therapeutics.”
Participation in the SoCalBio conference reflects Avesta Bio’s continued engagement with the Southern California biotechnology community as the company expands its investor and strategic partnership outreach.
About Avesta Bio
Avesta Bio is a translational oncology company developing first-in-class therapies that target fundamental cellular stress-response and drug-resistance pathways. By correcting maladaptive cellular programs implicated in cancer progression, the company aims to deliver safe and effective treatments for patients with high-unmet-need malignancies.
The company is advancing its lead program toward Phase I clinical evaluation through strategic partnerships supporting IND-enabling studies, GMP manufacturing, and global clinical development.
For more information, visit: www.avestabio.com